# Elicio Therapeutics, Inc.: financial statements, quarterly

ELTX · Nasdaq · CIK 1601485 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eltx.md) · [Financials](/companies/eltx/financials.md) · [Filings](/companies/eltx/filings.md) · [Insiders](/companies/eltx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eltx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [7.3](/filings/0001601485-24-000075.md) | [6.2 d](/filings/0001601485-25-000049.md) | [7.6](/filings/0001601485-25-000074.md) | [8.2](/filings/0001601485-25-000111.md) | [7.2](/filings/0001601485-25-000124.md) | [10.7 d](/filings/0001601485-26-000027.md) | [7.8](/filings/0001601485-26-000042.md) | [7.0](/filings/0001601485-26-000056.md) | [5.0](/filings/0001601485-25-000124.md) | [5.1 d](/filings/0001601485-26-000027.md) | [6.8](/filings/0001601485-26-000042.md) | [6.8](/filings/0001601485-26-000056.md) |
| Operating income | $m | [(10.8)](/filings/0001601485-24-000075.md) | [(9.4) d](/filings/0001601485-25-000049.md) | [(10.2)](/filings/0001601485-25-000074.md) | [(10.9)](/filings/0001601485-25-000111.md) | [(10.3)](/filings/0001601485-25-000124.md) | [(13.5) d](/filings/0001601485-26-000027.md) | [(10.7)](/filings/0001601485-26-000042.md) | [(10.1)](/filings/0001601485-26-000056.md) | [(8.0)](/filings/0001601485-25-000124.md) | [(8.8) d](/filings/0001601485-26-000027.md) | [(10.6)](/filings/0001601485-26-000042.md) | [(10.4)](/filings/0001601485-26-000056.md) |
| Interest expense | $m | [0.0](/filings/0001601485-23-000082.md) | [0.0 d](/filings/0001601485-24-000023.md) | [0.0](/filings/0001601485-24-000033.md) | [0.0](/filings/0001601485-25-000111.md) | [0.1](/filings/0001601485-25-000124.md) | [0.2 d](/filings/0001601485-26-000027.md) | [0.2](/filings/0001601485-26-000042.md) | [0.2](/filings/0001601485-26-000056.md) | [0.4](/filings/0001601485-25-000124.md) | [0.3 d](/filings/0001601485-26-000027.md) | [0.4](/filings/0001601485-26-000042.md) | [0.4](/filings/0001601485-26-000056.md) |
| Income tax | $m | [0.0](/filings/0001601485-24-000075.md) | [0.0 d](/filings/0001601485-25-000049.md) | [0.0](/filings/0001601485-25-000074.md) | [0.0](/filings/0001601485-25-000111.md) | [0.0](/filings/0001601485-25-000124.md) | [0.0 d](/filings/0001601485-26-000027.md) | [0.0](/filings/0001601485-26-000042.md) | [0.0](/filings/0001601485-26-000056.md) | [0.0](/filings/0001601485-25-000124.md) | [0.0 d](/filings/0001601485-26-000027.md) | [0.0](/filings/0001601485-26-000042.md) | [0.0](/filings/0001601485-26-000056.md) |
| Net income | $m | [(10.7)](/filings/0001601485-24-000075.md) | [(8.9) d](/filings/0001601485-25-000049.md) | [(11.8)](/filings/0001601485-25-000124.md) | [(7.2)](/filings/0001601485-25-000124.md) | [(18.8)](/filings/0001601485-25-000124.md) | [(14.0) d](/filings/0001601485-26-000027.md) | [(11.2)](/filings/0001601485-26-000056.md) | [(10.6)](/filings/0001601485-26-000056.md) | [(10.1)](/filings/0001601485-25-000124.md) | [(7.7) d](/filings/0001601485-26-000027.md) | [(11.8)](/filings/0001601485-26-000056.md) | [(8.2)](/filings/0001601485-26-000056.md) |
| Diluted EPS | $ per share | [(1.27)](/filings/0001601485-24-000075.md) | not reported | [(1.15)](/filings/0001601485-25-000074.md) | [(0.64)](/filings/0001601485-25-000111.md) | [(1.39)](/filings/0001601485-25-000124.md) | not reported | [(0.87)](/filings/0001601485-26-000042.md) | [(0.66)](/filings/0001601485-26-000056.md) | [(0.60)](/filings/0001601485-25-000124.md) | not reported | [(0.65)](/filings/0001601485-26-000042.md) | [(0.43)](/filings/0001601485-26-000056.md) |
| Basic EPS | $ per share | [(1.27)](/filings/0001601485-24-000075.md) | not reported | [(1.15)](/filings/0001601485-25-000074.md) | [(0.64)](/filings/0001601485-25-000111.md) | [(1.39)](/filings/0001601485-25-000124.md) | not reported | [(0.87)](/filings/0001601485-26-000042.md) | [(0.66)](/filings/0001601485-26-000056.md) | [(0.60)](/filings/0001601485-25-000124.md) | not reported | [(0.65)](/filings/0001601485-26-000042.md) | [(0.43)](/filings/0001601485-26-000056.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.8](/filings/0001601485-24-000075.md) | [12.9](/filings/0001601485-25-000049.md) | [11.9](/filings/0001601485-25-000074.md) | [3.4](/filings/0001601485-25-000111.md) | [26.0](/filings/0001601485-25-000124.md) | [17.6](/filings/0001601485-26-000027.md) | [18.4](/filings/0001601485-26-000042.md) | [22.1](/filings/0001601485-26-000056.md) | [20.6](/filings/0001601485-25-000124.md) | [18.6](/filings/0001601485-26-000056.md) | [14.9](/filings/0001601485-26-000042.md) | [23.5](/filings/0001601485-26-000056.md) |
| Current assets | $m | [19.9](/filings/0001601485-23-000082.md) | [16.3](/filings/0001601485-25-000049.md) | [14.1](/filings/0001601485-24-000033.md) | [6.7](/filings/0001601485-24-000045.md) | [30.6](/filings/0001601485-24-000075.md) | [20.7](/filings/0001601485-26-000027.md) | [20.9](/filings/0001601485-25-000074.md) | [22.6](/filings/0001601485-25-000111.md) | [21.5](/filings/0001601485-25-000124.md) | [19.3](/filings/0001601485-26-000056.md) | [16.2](/filings/0001601485-26-000042.md) | [25.5](/filings/0001601485-26-000056.md) |
| Total assets | $m | [31.0](/filings/0001601485-23-000082.md) | [27.1](/filings/0001601485-25-000049.md) | [24.5](/filings/0001601485-24-000033.md) | [15.8](/filings/0001601485-24-000045.md) | [38.4](/filings/0001601485-24-000075.md) | [28.2](/filings/0001601485-26-000027.md) | [28.1](/filings/0001601485-25-000074.md) | [29.5](/filings/0001601485-25-000111.md) | [28.3](/filings/0001601485-25-000124.md) | [25.9](/filings/0001601485-26-000056.md) | [22.7](/filings/0001601485-26-000042.md) | [31.3](/filings/0001601485-26-000056.md) |
| Current liabilities | $m | [11.5](/filings/0001601485-23-000082.md) | [9.8](/filings/0001601485-25-000049.md) | [6.0](/filings/0001601485-24-000033.md) | [7.6](/filings/0001601485-24-000045.md) | [9.0](/filings/0001601485-24-000075.md) | [11.5](/filings/0001601485-26-000027.md) | [11.4](/filings/0001601485-25-000074.md) | [9.9](/filings/0001601485-25-000111.md) | [6.5](/filings/0001601485-25-000124.md) | [8.1](/filings/0001601485-26-000056.md) | [7.2](/filings/0001601485-26-000042.md) | [9.2](/filings/0001601485-26-000056.md) |
| Total liabilities | $m | [17.7](/filings/0001601485-23-000082.md) | [15.8](/filings/0001601485-25-000049.md) | [19.6](/filings/0001601485-24-000033.md) | [17.4](/filings/0001601485-24-000045.md) | [57.4](/filings/0001601485-24-000075.md) | [39.5](/filings/0001601485-26-000027.md) | [19.2](/filings/0001601485-25-000074.md) | [27.7](/filings/0001601485-25-000111.md) | [24.5](/filings/0001601485-25-000124.md) | [24.2](/filings/0001601485-26-000056.md) | [24.1](/filings/0001601485-26-000042.md) | [23.4](/filings/0001601485-26-000056.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [20.0](/filings/0001601485-26-000027.md) | not reported | [9.3](/filings/0001601485-25-000111.md) | [9.7](/filings/0001601485-25-000124.md) | [9.4](/filings/0001601485-26-000056.md) | [9.5](/filings/0001601485-26-000042.md) | [9.5](/filings/0001601485-26-000056.md) |
| Shareholders' equity | $m | [13.3](/filings/0001601485-24-000075.md) | [11.4](/filings/0001601485-26-000027.md) | [4.9](/filings/0001601485-25-000124.md) | [(1.7)](/filings/0001601485-25-000124.md) | [(19.0)](/filings/0001601485-25-000124.md) | [(11.3)](/filings/0001601485-26-000056.md) | [8.9](/filings/0001601485-26-000056.md) | [1.8](/filings/0001601485-26-000056.md) | [3.8](/filings/0001601485-25-000124.md) | [1.6](/filings/0001601485-26-000056.md) | [(1.4)](/filings/0001601485-26-000056.md) | [7.9](/filings/0001601485-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.2) d](/filings/0001601485-24-000075.md) | [(9.9) d](/filings/0001601485-25-000049.md) | [(12.1)](/filings/0001601485-25-000074.md) | [(8.9) d](/filings/0001601485-25-000111.md) | [(7.3) d](/filings/0001601485-25-000124.md) | [(8.7) d](/filings/0001601485-26-000027.md) | [(10.1)](/filings/0001601485-26-000042.md) | [(9.0) d](/filings/0001601485-26-000056.md) | [(11.1) d](/filings/0001601485-25-000124.md) | [(6.8) d](/filings/0001601485-26-000027.md) | [(11.6)](/filings/0001601485-26-000042.md) | [(8.2) d](/filings/0001601485-26-000056.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001601485-24-000075.md) | [0.0 d](/filings/0001601485-25-000049.md) | [0.0](/filings/0001601485-24-000033.md) | [0.0 d](/filings/0001601485-25-000111.md) | [0.0 d](/filings/0001601485-25-000124.md) | [0.0 d](/filings/0001601485-26-000027.md) | not reported | not reported | [0.0 d](/filings/0001601485-25-000124.md) | [0.0 d](/filings/0001601485-26-000027.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.3](/filings/0001601485-23-000082.md) | [0.3](/filings/0001601485-24-000033.md) | [2.9](/filings/0001601485-24-000045.md) | [8.4](/filings/0001601485-24-000075.md) | [10.3](/filings/0001601485-25-000074.md) | [11.3](/filings/0001601485-25-000111.md) | [13.6](/filings/0001601485-25-000124.md) | [13.0](/filings/0001601485-26-000042.md) | [16.1](/filings/0001601485-26-000056.md) | [16.7](/filings/0001601485-25-000124.md) | [18.2](/filings/0001601485-26-000042.md) | [19.2](/filings/0001601485-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,281,882 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001601485-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.